15 Jan2014
In gamification milestone, Pfizer will assess video game in clinical trial for Alzheimer’s disease
In a move that could have a significant impact on how pharmaceutical companies view gamification, Pfizer (NYSE: PFE) has agreed to test the use of a mobile video game from Akili Interactive Labs to detect early signs of Alzheimer’s disease.
The goal of the trial is to evaluate Akili’s game as a biomarker for potential use in future Alzheimer’s trials, according to a company statement.
